Andre Goy - Regional Cancer Care Associates LLC

Andre Goy, M.D., M.S.


Chief Science Officer and Director of Research and Innovation

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely-known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma who had failed bortezomib. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

  • Medical Education: University Fourier, Grenoble, France
  • Internship and Residency: Internal medicine, Grenoble University Medical Center
  • Fellowship: Hematology/oncology, Grenoble University Medical Center
  • Graduate Training: MS in immunology, Pasteur Institute; MS in experimental oncology, Paris X University
  • Post-Doctoral Fellowship: Molecular oncology, Memorial Sloan-Kettering Cancer Center, New York City
  • Board Certifications: Internal medicine, hematology, medical oncology
  • Specializations: All types of lymphoma
  • Research Interests: Lymphoma, stem cell transplantation, cellular therapy, immunology and immunotherapy, molecular epidemiology
  • Memberships: American Society of Hematology, American Society of Clinical Oncology, American Medical Association